Swiss proof has to become legible to the American buyer.

• Basel pharma and life sciences. Roche, Novartis, Lonza, and the wider Basel pharma cluster, plus the long tail of family-controlled specialty pharma, generic, and contract-development firms that supply US health systems and US pharma primes.
• Zurich and Bern medtech. Ypsomed in Burgdorf, Sonova in Stäfa, Mathys in Bettlach, Medartis in Basel, Tecan in Männedorf, and the broader Swiss medical-device cluster bridging from CE-MDR to FDA 510(k), de novo, or PMA pathways for US health systems.
• Zentralschweiz precision machinery and food-processing equipment. Bühler in Uzwil for grain and food processing, Schindler in Ebikon for elevators and escalators, Stadler Rail in Bussnang for rail systems, Rieter in Winterthur for textile machinery, Schurter in Lucerne for industrial components.
• Aargau and Schaffhausen industrial cluster. ABB power and automation in Baden, Georg Fischer in Schaffhausen for piping systems, Bossard in Zug for fastening solutions, Bystronic in Niederönz for laser cutting, Mikron in Biel for high-precision tooling.
• Zürich and Geneva industrial software and fintech. Avaloq in Zurich, Temenos in Geneva, SoftwareONE in Stans, and the wider Swiss enterprise-software cluster carrying European bank, insurance, and industrial enterprise references into US enterprise procurement.
• Specialty chemicals, watchmaking-adjacent precision, and Ticino manufacturing. Sika in Baar for construction chemicals, Givaudan in Vernier for flavours and fragrances, plus the watchmaking-adjacent precision cluster supplying US aerospace, US defence, and US medical-device primes through component-level relationships.

• A US sales head hired into the existing frame. The hire inherits a Swiss-specification website, a credential-led deck, CHF-denominated quotes, and a follow-up cadence calibrated for a Swiss buyer. Twelve months in, the hire has not closed enough to justify the cost.
• A US subsidiary opened without the commercial layer rebuilt. A Delaware C-Corp registered, a US bank account opened, a Carolinas, Boston biotech corridor, or San Diego medical-device corridor lease signed. The website still opens with company history and SQS-mode capability descriptions.
• Switzerland Global Enterprise trade-mission presence as the entry channel. Trade-mission stands and bilateral meetings with translated home-market materials. The conversations are warm. The post-mission follow-up does not convert because the US-facing surface the buyer visits next is still the home-market register.
• English translation of the home-market website. Done by an internal team or by the Swiss agency that built the home site. The technical accuracy is high. The commercial register is unchanged.
• A US distributor, rep, or integrator signed. A small US firm signed under a distribution agreement that solves logistics but cannot represent the firm in the US procurement conversation. The buyer still expects the manufacturer to carry the commercial frame.
• A US-based clinical or technical liaison. A single US clinical specialist or technical engineer near a major US health system or US OEM customer. The technical service is excellent. The commercial pipeline beyond the anchor account does not develop.

• SQS, SAS, SIA, CE, MDR, ISO 9001, ISO 13485, and ISO 27001 lead the trust signals. In Switzerland they form the category. In the United States they are administrative checkboxes.
• Specifications written in CE, MDR, and Swiss precision register read as engineering brochure rather than as commercial offer. The US procurement officer wants the category, the US installed base or peer set, the named US customers, and the service architecture before the specification page.
• Multi-decade Swiss operating reputation and quiet trust signals carry the credibility load on the home-market site. The US reader scans past the founding date and the Swiss-quality references looking for the US category claim and finds none.
• CHF-denominated price lists held back until the relationship warms. US procurement expects firm USD pricing on the table at quote stage. Withheld pricing reads as commercial inexperience rather than as Swiss discretion.
• US-side service, parts, uptime, and clinical-support architecture is missing or buried. US plants and US health systems require a US-readable answer before the order moves.
• Geschäftsführer biographies lead with ETH Zurich or EPFL chairs, FH or HSG titles, and federal commission posts. The US reader is looking for a US peer who has installed at a comparable US plant or hospital system and finds a credential file instead.
• The follow-up cadence is calibrated for a European procurement clock with Swiss reserve. Two weeks of considered silence reads as care in Switzerland and as disinterest in the United States. The opportunity is gone before the Swiss team has reopened the file.

The product is not the problem. The Swiss precision is not the problem. The US-facing frame around the product is, and the frame is fixable.